Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 1.00 |
| ▸ | AOC2 | O75106 | 5/20 | 1.00 |
| ▸ | MAOA | P21397 | 5/20 | 1.00 |
| ▸ | AOC3 | Q16853 | 2/20 | 1.00 |
| ▸ | DAO | P14920 | 2/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mofegiline SCHEMBL1295041 | 1.00 | MAOB (1.00) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL1295043 | 1.00 | MAOB (1.00) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL14005358 | 1.00 | MAOB (1.00) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL343685 | 0.98 | MAOB (0.96) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL125286 | 0.98 | MAOB (0.96) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL343686 | 0.98 | MAOB (0.96) | MAOBAOC2MAOAAOC3DAO | |
| SCHEMBL1295016 | 0.84 | MAOB (0.72) | MAOBAOC2MAOAAOC3DAO | |
| SCHEMBL1295522 | 0.84 | MAOB (0.72) | MAOBAOC2MAOAAOC3DAO | |
| SCHEMBL1294767 | 0.84 | MAOB (0.72) | MAOBAOC2MAOAAOC3DAO | |
| SCHEMBL1295015 | 0.84 | MAOB (0.72) | MAOBAOC2MAOAAOC3DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1085 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20200188388-A1 | METHODS AND COMPOSITIONS FOR POTENTIATING CNS DRUGS AND REDUCING THEIR SIDE EFFECTS | SYNNERVA LTD. (IL) | 2020-06-18 | — | — | US | claimed |
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | PROXIMAGEN, LLC (US) | 2020-05-14 | — | — | US | claimed |
| EP-3634393-A1 | INHIBITORS OF VASCULAR ADHESION PROTEIN-1 FOR USE IN PREVENTION OR TREATMENT OF MIGRAINE | PROXIMAGEN, LLC (US) | 2020-04-15 | — | — | EP | claimed |
| EP-3562477-A1 | METHODS AND COMPOSITIONS FOR POTENTIATING CNS DRUGS AND REDUCING THEIR SIDE EFFECTS | Rvx Therapeutics Ltd. (IL) | 2019-11-06 | — | — | EP | claimed |
| CN-110337289-A | Methods and compositions for enhancing CNS drugs and reducing their side effects | RVX疗法有限公司 | 2019-10-15 | — | — | CN | claimed |
| WO-2018224837-A1 | INHIBITORS OF VASCULAR ADHESION PROTEIN-1 FOR USE IN PREVENTION OR TREATMENT OF MIGRAINE | Proximagen Group Limited (GB) | 2018-12-13 | — | — | WO | claimed |
| WO-2018122845-A1 | METHODS AND COMPOSITIONS FOR POTENTIATING CNS DRUGS AND REDUCING THEIR SIDE EFFECTS | RVX THERAPEUTICS LTD. (IL) | 2018-07-05 | — | — | WO | claimed |
| WO-2016037166-A1 | NOVEL ANTI-OXIDANT COMPOSITIONS AND METHODS OF DELIVERY | ZHANG YU (US) | 2016-03-10 | — | — | WO | claimed |
| EP-2961730-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XenoPort, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061537-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| EP-1028719-A1 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER AND NARCOLEPSY | R.P. Scherer Technologies, Inc. (US) | 2000-08-23 | — | — | EP | claimed |
| WO-2000045846-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE OR A LIGAND OF NICOTINE RECEPTORS AND A MONAMINE OXYDASE INHIBITOR AND THEIR USE FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | SANOFI-SYNTHELABO (FR) | 2000-08-10 | — | — | WO | claimed |
| WO-1999013879-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MONOAMINE OXYDASE INHIBITOR AND THEIR USE IN THERAPY | SANOFI-SYNTHELABO (FR) | 1999-03-25 | — | — | WO | claimed |
| WO-1999003458-A1 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER AND NARCOLEPSY | R.P. SCHERER LIMITED (GB) | 1999-01-28 | — | — | WO | claimed |
| CN-1178461-A | Pharmaceutical compositions comprising monoamine oxidase B inhibitors | SCHERER LTD R P (GB) | 1998-04-08 | — | — | CN | claimed |
| EP-0814789-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOAMINE OXIDASE B INHIBITORS | R.P. Scherer Limited (GB) | 1998-01-07 | — | — | EP | claimed |
| WO-1996026720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOAMINE OXIDASE B INHIBITORS | R.P. SCHERER LIMITED (GB) | 1996-09-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, SMOX | MAOB 18/4885AOC2 5/4885MAOA 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.